JERUSALEM, Jan 20, 2022 – Alpha Tau Medical Ltd. (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has signed a sponsored research agreement with investigators at The University of Texas MD Anderson Cancer Center (“MD Anderson”) to evaluate potential immune stimulation by combining Alpha DaRT™ with DNA-repair inhibitors and immune checkpoint inhibitors for the treatment of breast tumors. The study will be led by
Alpha Tau Announces Results of First US Clinical Trial of Alpha DaRT™ in Malignant Skin & Soft Tissue Cancers, Showing Complete Response in All Ten Treated Tumors at Approximately 12 Weeks and No Product-Related Serious Adverse Events JERUSALEM, Jan. 10, 2022 -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that all ten patients in its US multi-center pilot trial of the Alpha DaRT for malignan
JERUSALEM, Dec. 31, 2021 -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has been notified by HekaBio K.K., its clinical trial partner in Japan, that recruitment has been completed in its open-label multi-center pivotal study evaluating the Alpha DaRT in Japanese patients with recurrent Head & Neck cancer after radiotherapy. HekaBio has reported that preliminary results of this trial
Coming Up Soon - Alpha DaRT Investigator Meeting in Las Vegas Alpha Tau is pleased to announce that the Alpha DaRT Investigator Meeting, for investigators participating in the US Multicenter Pivotal Study for Skin Cancer, will be held in Las Vegas Nevada, February 27-28. We look forward to seeing our clinical collaborators at The Venetian Resort Las Vegas!